TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15738450

Group type: EXPERIMENTAL
Intervention: Special intervention group (nutrition counseling, smoking cessation, increased physical activity, intensive blood pressure treatment)
Number of subjects: 11827

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 11827

Group type: EXPERIMENTAL
Intervention: Special intervention group among smokers (63% of participants)
Number of subjects: 11827

Group type: EXPERIMENTAL
Intervention: Special intervention group among nonsmokers (37% of participants)
Number of subjects: 11827
Study: 12925557

Group type: EXPERIMENTAL
Intervention: Perindopril-based blood pressure-lowering regimen
Number of subjects: 6105
Study: 10394517

Group type: EXPERIMENTAL
Intervention: Uterine embolization
Number of subjects: 51
Study: 9012194

Group type: EXPERIMENTAL
Intervention: Auto Adjust CPAP
Number of subjects: 12

Group type: COMPARATOR
Intervention: Constant CPAP
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Total sleep-time, sleep efficiency and sleep stages
Number of subjects: 12
Study: 8101900

Group type: EXPERIMENTAL
Intervention: Endoscopic variceal banding ligation
Number of subjects: 103

Group type: COMPARATOR
Intervention: Injection sclerotherapy
Number of subjects: 103
Study: 3786346

Group type: EXPERIMENTAL
Intervention: Nicotine chewing gum (2 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nicotine chewing gum (4 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (0 mg nicotine gum)
Number of subjects: 12
Study: 29071356

Group type: EXPERIMENTAL
Intervention: Patient-specific instrumentation (PSI)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Standard instrumentation (SI)
Number of subjects: 125
Study: 27683846

Group type: EXPERIMENTAL
Intervention: Clobazam (0.5 mg·kg‐1·d‐1, adjustable up to 2.0 mg·kg‐1·d‐1, maximum 80 mg/d)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Clobazam
Number of subjects: 200
Study: 23837461

Group type: EXPERIMENTAL
Intervention: Zonisamide (1 mg/kg/day titrated to 8 mg/kg/day over 8 weeks, maintained for 12 weeks)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Zonisamide
Number of subjects: 207
Study: 20942843

Group type: EXPERIMENTAL
Intervention: Gem-(R)CHOP
Number of subjects: 25

Group type: COMPARATOR
Intervention: (R)CHOP
Number of subjects: 25
Study: 21299184

Group type: EXPERIMENTAL
Intervention: Thai traditional massage (TTM)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Chinese acupuncture
Number of subjects: 18
Study: 17488363

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (RSG) 4 mg twice daily for 6 weeks
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 15371860

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 72

Group type: COMPARATOR
Intervention: 0.9% normal saline (placebo)
Number of subjects: 72
Study: 11354518

Group type: EXPERIMENTAL
Intervention: 10 mg of temazepam
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 9059318

Group type: EXPERIMENTAL
Intervention: Electrical oesophageal stimulation (200 microns, 16 mA, 0.2 Hz)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Mechanical oesophageal stimulation (0.5 s, 14 ml, 0.2 Hz)
Number of subjects: 14
Study: 8126629

Group type: EXPERIMENTAL
Intervention: Curosurf (natural surfactant)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Exosurf (synthetic surfactant)
Number of subjects: 66
Study: 3117877

Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 30170410

Group type: EXPERIMENTAL
Intervention: Core Strength Training (CST) for 1 hour per day, 5 days per week for 12 weeks
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan (TCC) for 1 hour per day, 5 days per week for 12 weeks
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Combined CST and TCC for 30 minutes each per day, 5 days per week for 12 weeks
Number of subjects: 384

Group type: COMPARATOR
Intervention: No specific exercises (Control group)
Number of subjects: 384
Study: 26909882

Group type: EXPERIMENTAL
Intervention: LA Sprouts intervention
Number of subjects: 319

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 319
Study: 24210765

Group type: EXPERIMENTAL
Intervention: EX-PRESS
Number of subjects: 120

Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 120
Study: 23435159

Group type: EXPERIMENTAL
Intervention: Basal-bolus regimen with glargine once daily and glulisine before meals
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Basal plus regimen with glargine once daily and supplemental doses of glulisine
Number of subjects: 375

Group type: COMPARATOR
Intervention: Sliding scale regular insulin (SSI)
Number of subjects: 375
Study: 20102616

Group type: EXPERIMENTAL
Intervention: Computerised clinical decision support (CCDS) software used by paramedics
Number of subjects: 60

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 60
Study: 19123335

Group type: EXPERIMENTAL
Intervention: Colonic dripping with Taihuang liquid (THL)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Conventional treatment and nursing (Control)
Number of subjects: 138
Study: 16095766

Group type: EXPERIMENTAL
Intervention: Three doses of SsWC on Days 0, 14, and 28 (N = 3)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Five doses of SsWC on Days 0, 2, 4, 6, and 28 (N = 4)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (N = 3)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both dosing regimens of SsWC
Number of subjects: 10
Study: 12912816

Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg single dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metoprolol (100 mg single dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg BID for 6 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metoprolol (200 mg extended-release daily for 6 months)
Number of subjects: 0
Study: 10792115

Group type: EXPERIMENTAL
Intervention: Omeprazole (40 mg o.d.)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Omeprazole/diclofenac
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo/diclofenac
Number of subjects: 12
Study: 8852907

Group type: EXPERIMENTAL
Intervention: Trivalent oral polio vaccine (OPV)
Number of subjects: 0
Study: 2060435

Group type: EXPERIMENTAL
Intervention: d-fenfluramine (15 mg/day for 1 week)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6689058

Group type: EXPERIMENTAL
Intervention: DSIP (delta-sleep-inducing-peptide)
Number of subjects: 0
Study: 31021381

Group type: EXPERIMENTAL
Intervention: Nonneovascular AMD in the fellow eye
Number of subjects: 686
Study: 27790756

Group type: EXPERIMENTAL
Intervention: Adapalene 0.1%/benzoyl peroxide 2.5% gel (A/BPO)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 31
Study: 27477059

Group type: EXPERIMENTAL
Intervention: Average nightly sleep duration at 4th grade
Number of subjects: 709

Group type: EXPERIMENTAL
Intervention: Inhibitory control (EF subdomain)
Number of subjects: 709

Group type: EXPERIMENTAL
Intervention: Organization of materials (EF subdomain)
Number of subjects: 709

Group type: EXPERIMENTAL
Intervention: Delay of weekend bed‐ or wake‐times
Number of subjects: 709
Study: 24310444

Group type: EXPERIMENTAL
Intervention: PULSED orosensory stimulation through a pneumatically charged pacifier
Number of subjects: 160

Group type: COMPARATOR
Intervention: SHAM control (blind pacifier)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: PULSED orosensory stimulation
Number of subjects: 160
Study: 22209048

Group type: EXPERIMENTAL
Intervention: Endotracheal tube cuff management
Number of subjects: 0
Study: 19036353

Group type: EXPERIMENTAL
Intervention: Relaxation training plus concreteness training
Number of subjects: 2

Group type: COMPARATOR
Intervention: Relaxation training
Number of subjects: 2
Study: 17385938

Group type: EXPERIMENTAL
Intervention: Drospirenone in combination with estrogen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral progestogen preparations (control)
Number of subjects: 0
Study: 15735107

Group type: EXPERIMENTAL
Intervention: Daily multiple micronutrient (DMM) supplement
Number of subjects: 1134

Group type: EXPERIMENTAL
Intervention: Weekly multiple micronutrient (WMM) supplement
Number of subjects: 1134

Group type: EXPERIMENTAL
Intervention: Daily iron (DI) supplements
Number of subjects: 1134

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 1134
Study: 11960302

Group type: EXPERIMENTAL
Intervention: Energy-restricted diet plan of 5.2-6.3 MJ/day with nutrient-fortified liquid meal replacement (MR) for group B.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Energy-restricted diet plan of 5.2-6.3 MJ/day without nutrient-fortified liquid meal replacement for group A.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Energy-restricted diet plan of 5.2-6.3 MJ/day with MR for group B.
Number of subjects: 100

Group type: COMPARATOR
Intervention: Energy-restricted diet plan of 5.2-6.3 MJ/day without MR for group A.
Number of subjects: 100
Study: 10215730

Group type: EXPERIMENTAL
Intervention: Ranitidine 75 mg
Number of subjects: 284

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study: 8846749

Group type: EXPERIMENTAL
Intervention: L-propionyl carnitine (2 g by slow infusion b.i.d, plus heparin and buflomedil)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (plus heparin and buflomedil)
Number of subjects: 12
Study: 2361811

Group type: EXPERIMENTAL
Intervention: Moderate duration exercise (M‐EX)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Long duration exercise (L‐EX)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No exercise (NO‐EX)
Number of subjects: 12
Study: 389824

Group type: EXPERIMENTAL
Intervention: Bacampicillin 400 mg plus 1 g probenecid
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: Bacampicillin 800 mg plus 1 g probenecid
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: Bacampicillin 1600 mg plus 1 g probenecid
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: Bacampicillin (all doses)
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: Bacampicillin 1600 mg
Number of subjects: 883
Study: 31918929

Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Cobalt-chromium everolimus-eluting stent
Number of subjects: 400
Study: 30984998

Group type: EXPERIMENTAL
Intervention: Spinal Anesthesia (SA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 100
Study: 26187147

Group type: EXPERIMENTAL
Intervention: Active rTMS treatment (10Hz for 3 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham rTMS treatment
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Active rTMS treatment
Number of subjects: 24
Study: 23039313

Group type: EXPERIMENTAL
Intervention: Nurse-completed nutrition screening
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (no nurse-completed nutrition screening)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Referred patients
Number of subjects: 81

Group type: COMPARATOR
Intervention: Non-referred patients
Number of subjects: 81
Study: 21823783

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Stress Management Training
Number of subjects: 73
Study: 19134532

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 885

Group type: COMPARATOR
Intervention: Cyclosporine microemulsion
Number of subjects: 885

Group type: EXPERIMENTAL
Intervention: Tacrolimus and Cyclosporine microemulsion
Number of subjects: 885
Study: 16999746

Group type: EXPERIMENTAL
Intervention: Randomized clinical trial designed to reduce HIV sexual risk behavior
Number of subjects: 106
Study: 12630982

Group type: EXPERIMENTAL
Intervention: Clozapine treatment (n = 54)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Healthy control group (n = 56)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Mood disorder patients (n = 36)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Schizophrenics not treated with clozapine (n = 41)
Number of subjects: 191
Study: 10715931

Group type: EXPERIMENTAL
Intervention: Power toothbrush (Braun Oral‐B Ultra Plaque Remover, Braun GmbH)
Number of subjects: 16903
Study: 9379381

Group type: EXPERIMENTAL
Intervention: Healon GV
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healon
Number of subjects: 60
Study: 1529284

Group type: EXPERIMENTAL
Intervention: Fish oil (10 g/day)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control
Number of subjects: 43
Study: 2868467

Group type: EXPERIMENTAL
Intervention: Prophylactic maintenance medication
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neuroleptic crisis intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylactic early intervention
Number of subjects: 0
Study: 31227284

Group type: EXPERIMENTAL
Intervention: Elagolix 150 mg once a day
Number of subjects: 1298

Group type: EXPERIMENTAL
Intervention: Elagolix 200 mg twice a day
Number of subjects: 1298

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1298
Study: 29950019

Group type: EXPERIMENTAL
Intervention: Scalable randomized algorithm for estimating variance components in linear mixed models (LMMs)
Number of subjects: 500000

Group type: EXPERIMENTAL
Intervention: Standard hardware implementation of the proposed method
Number of subjects: 500000
Study: 29394018

Group type: EXPERIMENTAL
Intervention: C‐T (cream applied with repeated toner every 2 h)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: C+T (cream and toner applied successively)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: T+C (toner and cream applied successively)
Number of subjects: 7

Group type: COMPARATOR
Intervention: C (cream only)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: C‐S (cream applied with repeated spray water every 2 h)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: T‐T (toner applied with repeated toner every 2 h)
Number of subjects: 7

Group type: COMPARATOR
Intervention: N (untreated group)
Number of subjects: 7
Study: 24675035

Group type: EXPERIMENTAL
Intervention: Covered double-layered stent
Number of subjects: 134

Group type: COMPARATOR
Intervention: Uncovered unfixed-cell braided stent
Number of subjects: 134
Study: 23033520

Group type: EXPERIMENTAL
Intervention: HIV antibody test
Number of subjects: 0

Group type: COMPARATOR
Intervention: DNA polymerase chain reaction (PCR) testing
Number of subjects: 0
Study: 19716013

Group type: EXPERIMENTAL
Intervention: MPH (microporous polysaccharide hemospheres)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (untreated side)
Number of subjects: 40
Study: 18089865

Group type: EXPERIMENTAL
Intervention: Gemcitabine infusion over 100 minutes
Number of subjects: 33

Group type: COMPARATOR
Intervention: Gemcitabine infusion over 30 minutes
Number of subjects: 33
Study: 15329586

Group type: EXPERIMENTAL
Intervention: Recruitment maneuver (sustained inflation of 50 cm H2O for 30 s)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no recruitment maneuver)
Number of subjects: 30
Study: 19260180

Group type: EXPERIMENTAL
Intervention: Auditory model present
Number of subjects: 48

Group type: COMPARATOR
Intervention: Auditory model absent
Number of subjects: 48
Study: 9702852

Group type: EXPERIMENTAL
Intervention: 0.5 mg of digoxin alone (Phase 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.5 mg of digoxin after 200 mg of acarbose (Phase 2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.5 mg of digoxin after 100 mg of acarbose (Phase 3)
Number of subjects: 0
Study: 7978671

Group type: EXPERIMENTAL
Intervention: Local anesthesia
Number of subjects: 80

Group type: COMPARATOR
Intervention: Spinal anesthesia
Number of subjects: 80
Study: 2657105

Group type: EXPERIMENTAL
Intervention: Yohimbine hydrochloride (maximum of 42.0 mg orally daily)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 4938431

Group type: EXPERIMENTAL
Intervention: Levodopa (maximum tolerated dosage)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Levodopa + L-alpha-methyldopahydrazine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (Levodopa alone)
Number of subjects: 21
Study: 31432432

Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 40

Group type: COMPARATOR
Intervention: Light physical exercise
Number of subjects: 40
Study: 29847672

Group type: EXPERIMENTAL
Intervention: PF-04634817 200 mg once-daily (QD) plus placebo
Number of subjects: 199

Group type: COMPARATOR
Intervention: Ranibizumab 0.3/0.5 mg monthly plus oral placebo
Number of subjects: 199
Study: 28129746

Group type: EXPERIMENTAL
Intervention: Graded Exercise Therapy (GET)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 0
Study: 26371113

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 11801

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 11801
Study: 23104718

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 145

Group type: COMPARATOR
Intervention: Oral care education
Number of subjects: 145
Study: 21664811

Group type: EXPERIMENTAL
Intervention: sorafenib 400mg bid
Number of subjects: 458

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 458
Study: 17414674

Group type: EXPERIMENTAL
Intervention: Lacidipine
Number of subjects: 1523

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 1523
Study: 15176768

Group type: EXPERIMENTAL
Intervention: Hallucination focused integrative treatment (HIT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 0
Study: 12487889

Group type: EXPERIMENTAL
Intervention: Autogenous bone as orbital grafting material
Number of subjects: 21

Group type: COMPARATOR
Intervention: HA composite material as orbital grafting material
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Late reconstruction of the orbit and reposition of the globe
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Surgical intervention
Number of subjects: 21
Study: 9806657

Group type: EXPERIMENTAL
Intervention: Combination treatment with carboplatin (600 mg/m2 on Day 1), cyclophosphamide (250 mg/m2 on Day 1), and cisplatin (100 mg/m2 on Day 8 every 4 weeks) with or without amifostine (740‐1140 mg/m2)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Combination treatment with carboplatin, cyclophosphamide, and cisplatin
Number of subjects: 26
Study: 7661678

Group type: EXPERIMENTAL
Intervention: Fibrin glue
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control
Number of subjects: 56
Study: 2679048

Group type: EXPERIMENTAL
Intervention: Nifedipine (10-30 mg before meals)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 1008540

Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 0
Study: 31888732

Group type: EXPERIMENTAL
Intervention: Medication Therapy Management (MTM) intervention
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 28210027

Group type: EXPERIMENTAL
Intervention: Klapp method (20 sessions, three times a week)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Inactive control group (no intervention)
Number of subjects: 22
Study: 25872929

Group type: COMPARATOR
Intervention: Sham SM
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Mobilization
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Manipulation
Number of subjects: 216
Study: 23308171

Group type: EXPERIMENTAL
Intervention: Hyperglycemia (plasma glucose levels 14.1 ± 2.6 mM for T2D-HF)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Hyperglycemia (plasma glucose levels 9.9 ± 2.1 mM for T2D-nonHF)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Hyperglycemia
Number of subjects: 18

Group type: COMPARATOR
Intervention: Normoglycemia
Number of subjects: 18
Study: 21056926

Group type: EXPERIMENTAL
Intervention: Recovery after 5 years
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Employment or studying status after 5 years
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Presence of psychotic symptoms among those working
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Recovery predictors
Number of subjects: 255
Study: 18371107

Group type: EXPERIMENTAL
Intervention: COPAD chemotherapy (cyclophosphamide, vincristine, prednisolone, and doxorubicin), given in two courses without intrathecal chemotherapy.
Number of subjects: 132
Study: 16436174

Group type: EXPERIMENTAL
Intervention: Bath PUVA
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Oral PUVA
Number of subjects: 8
Study: 15452093

Group type: EXPERIMENTAL
Intervention: Hyperglycemia (15 mM blood glucose)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Euglycemia (5 mM blood glucose)
Number of subjects: 14
Study: 11579649

Group type: EXPERIMENTAL
Intervention: Combination of rifampicin 600 mg plus ofloxacin 400 mg plus minocycline 100 mg (ROM) administered as single dose
Number of subjects: 236

Group type: COMPARATOR
Intervention: Standard WHO/MDT/PB six months regimen
Number of subjects: 236
Study: 9822485

Group type: EXPERIMENTAL
Intervention: Intramuscular dexamethasone (6 mg every 12 hours for 4 doses, repeated weekly until 34 weeks' gestation)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Oral dexamethasone (8 mg every 12 hours for 4 doses, repeated weekly until 34 weeks' gestation)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Oral dexamethasone
Number of subjects: 170
Study: 7858362

Group type: EXPERIMENTAL
Intervention: i.v.‐PCA ketorolac 5 mg/ml
Number of subjects: 70

Group type: COMPARATOR
Intervention: i.v.‐PCA morphine 1 mg/ml
Number of subjects: 70
Study: 2698170

Group type: EXPERIMENTAL
Intervention: PABA-serum concentration in patients with normal pancreatic function
Number of subjects: 0

Group type: COMPARATOR
Intervention: PABA-serum concentration in patients with exocrine pancreatic insufficiency
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pharmacologic inhibition using pirenzepine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Urine-PABA concentrations in patients with exocrine pancreatic insufficiency
Number of subjects: 0
Study: 1020533

Group type: EXPERIMENTAL
Intervention: Trichloroethylene (TCE) exposure at 100 ppm for 5 days
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo exposure
Number of subjects: 7